Showing 61 - 70 of 89
Persistent link: https://www.econbiz.de/10001750927
Persistent link: https://www.econbiz.de/10001734799
In jüngster Vergangenheit hat die Versicherungswirtschaft einen grundlegenden Wandel durchlaufen. Deregulierung, Globalisierung sowie Substitutionskonkurrenz führten zu einem verschärften Wettbewerb um Marktanteile bei sinkenden Gewinnmargen.Aufgrund dieser neuen Wettbewerbsdynamik und den...
Persistent link: https://www.econbiz.de/10005846642
Persistent link: https://www.econbiz.de/10009124316
Background: The EQ-5D-5L questionnaire is used in oncology to generate health-related quality of life (HRQoL) weights and corresponding health states. The purpose was to explore the relationship between demographic and clinical characteristics and HRQoL among advanced or metastatic colorectal...
Persistent link: https://www.econbiz.de/10012391016
Background: Allergic Rhinitis (AR) is a common disorder in Europe with Allergic Asthma (AA) as a frequent comorbidity. Allergy immunotherapy (AIT) is the only causal therapy of AR and AA, and can be administered as subcutaneous injections at the physician or as sublingual drops or tablets at...
Persistent link: https://www.econbiz.de/10011586476
Marked differences in costs between subcutaneous and intravenous therapies were observed. Among the three groups of patients defined by TNF inhibitor treatment, costs for the infliximab group were highest during the year after the index event. </AbstractSection> Copyright Zeidler et al.; licensee Springer. 2012
Persistent link: https://www.econbiz.de/10010998805
<Para ID="Par6">Given a sufficient data supply, DES is the modeling technique of choice when modeling cost-effectiveness in RA. Otherwise transparency on the data inputs is crucial for valid results and to inform decision makers about possible biases. With regard to ICERs, Markov models might provide similar...</para>
Persistent link: https://www.econbiz.de/10010998811
Costs of outpatient medication for CF patients significantly depend on age, co-morbidities and other clinical parameters. Hence, non-optimal treatment could lead to a significantly higher burden for the healthcare system. </AbstractSection> Copyright Adis Data Information BV 2010
Persistent link: https://www.econbiz.de/10011000838
Pharmacogenomic profiling has the potential to improve the cost effectiveness of pharmaceutical treatment in mCRC. Hence, quantification of the economic impact of stratified medicine as well as cost-effectiveness analyses of pharmacogenomic profiling are becoming more important. Nevertheless,...
Persistent link: https://www.econbiz.de/10011001668